Prolacta Bioscience appoints David Steinberg as CFO
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Subscribe To Our Newsletter & Stay Updated